Chest Medicine
Lilly antibody drug fails in a Covid-19 study; others go on
28 Oct, 2020 | 09:10h | UTCLilly antibody drug fails in a Covid-19 study; others go on – CNBC
Outpatient management of COVID-19: Rapid evidence review
28 Oct, 2020 | 09:11h | UTCOutpatient Management of COVID-19: Rapid Evidence Review – American Family Physician
Chest CT in COVID-19: What the radiologist needs to know
28 Oct, 2020 | 08:59h | UTCChest CT in COVID-19: What the Radiologist Needs to Know – RadioGraphics
Preventing the spread of SARS-CoV-2 with masks and other “low-tech” interventions
27 Oct, 2020 | 09:51h | UTCPreventing the Spread of SARS-CoV-2 With Masks and Other “Low-tech” Interventions – JAMA
Commentary on Twitter
The essentiality of 😷😷 and low-tech tools even when vaccination programs are getting implemented. And call for universal masking now. https://t.co/Egyh0vjn5S by @NIAIDNews Andrea Lerner, Tony Fauci @JAMA_current pic.twitter.com/E1QeUW2bpE
— Eric Topol (@EricTopol) October 26, 2020
COVID-19 – Lessons learned and questions remaining
27 Oct, 2020 | 09:46h | UTCCOVID-19 – Lessons Learned and Questions Remaining – Clinical Infectious Diseases
Commentary on Twitter
🔥Excellent article🔥
COVID-19 – Lessons Learned and Questions Remaining@CarlosdelRio7 @davidantibiotic https://t.co/c0VG4yyJXO pic.twitter.com/7Bxn1mVttT— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) October 26, 2020
[Preprint] Randomized trial: Nitazoxanide does not improve symptoms in mild Covid-19 disease
25 Oct, 2020 | 23:46h | UTCEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial – medRxiv
Clinical Update: Virology, transmission, and pathogenesis of SARS-CoV-2
25 Oct, 2020 | 23:48h | UTCVirology, transmission, and pathogenesis of SARS-CoV-2 – The BMJ
Commentary on Twitter
https://twitter.com/bmj_latest/status/1320425173976256513
Perspective: The race to make COVID antibody therapies cheaper and more potent
25 Oct, 2020 | 23:43h | UTCThe race to make COVID antibody therapies cheaper and more potent – Nature
Review: How to ventilate obese patients in the ICU
25 Oct, 2020 | 23:30h | UTCHow to ventilate obese patients in the ICU – Intensive Care Medicine (free for a limited period)
Commentary on Twitter
https://twitter.com/yourICM/status/1319623153283440640
Down syndrome tied to 10 times the risk of COVID-19 death
23 Oct, 2020 | 09:13h | UTCDown syndrome tied to 10 times the risk of COVID-19 death – CIDRAP
Original study: COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults – Annals of Internal Medicine
Randomized trial: Convalescent plasma ineffective for patients hospitalized with Covid-19
23 Oct, 2020 | 09:15h | UTCEditorial: Convalescent plasma is ineffective for covid-19 – The BMJ
Commentary on Twitter
Just published @bmj_latest: A randomized trial of convalescent plasma for moderate covidhttps://t.co/dUvEMFSLHG
No benefit. It was underpowered to detect mortality reduction with 464 patients. A large RCT is needed to resolve the question, but these findings are not encouraging. pic.twitter.com/WGtz9IVSZe— Eric Topol (@EricTopol) October 23, 2020
Pro/con debate: Therapeutic anticoagulation in hospitalized patients with Covid-19 without established thromboembolism
23 Oct, 2020 | 09:12h | UTCAnticoagulation in Hospitalized Patients with Covid-19 – New England Journal of Medicine
Related editorial: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence – Journal of the American College of Cardiology
Study: COVID-19 is at least 5 times deadlier than flu for hospitalized patients
23 Oct, 2020 | 09:09h | UTCCOVID-19 is at least 5 times deadlier than flu for hospitalized patients – LiveScience
Commentary on Twitter
Patients hospitalized in @VeteransHealth facilities for #COVID19 were at higher risk for serious complications and death than those hospitalized for flu, a new MMWR report finds. Learn more: https://t.co/66ry7TJon4. pic.twitter.com/rCKMsVS03b
— CDC (@CDCgov) October 20, 2020
Podcast: Deep vein thrombosis and pulmonary embolism
23 Oct, 2020 | 08:58h | UTC#238 DVT / PE Triple Distilled – The Curbsiders Internal Medicine Podcast
Guidelines for evaluation and management of pulmonary disease in Sjögren’s
23 Oct, 2020 | 08:57h | UTCConsensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s – CHEST
Randomized trial: Tocilizumab does not improve outcomes for patients hospitalized with Covid-19
22 Oct, 2020 | 09:42h | UTCEfficacy of Tocilizumab in Patients Hospitalized with Covid-19 – New England Journal of Medicine
New calculator predicts risk of hospital admission and mortality from coronavirus 19 in adults
22 Oct, 2020 | 09:37h | UTCSee calculator: QCovid® risk calculator
Commentary on Twitter
A new "living" high quality prediction model for #COVID19 risk for hospitalization and mortality: top 20% risk accounted for 94% of deaths; https://t.co/aPXRM2pHCq calculatorhttps://t.co/gdd8b3j33K @bmj_latest
by @AshClift @JuliaHCox @OxPrimaryCare and colleagues pic.twitter.com/s8TrWWECb0— Eric Topol (@EricTopol) October 21, 2020
Imaging features and differential diagnoses of non-neoplastic diffuse mediastinal diseases
22 Oct, 2020 | 09:26h | UTC
ATS Conference coverage: Many patients prescribed home oxygen after an acute COPD exacerbation no longer meet the criteria two to three months later
22 Oct, 2020 | 09:25h | UTCBreathing easier from hospital to home – ACP Internist
Studies offer little hope for Tocilizumab in treating COVID
21 Oct, 2020 | 09:27h | UTCStudies offer little hope for tocilizumab in treating COVID – CIDRAP
See studies: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 – JAMA Internal Medicine AND Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine AND Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine
Commentary: expert reaction to three studies of Tocilizumab to treat COVID patients – Science Media Centre
Related study (preprint): Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Studies point to big drop in COVID-19 death rates
21 Oct, 2020 | 09:23h | UTCStudies Point To Big Drop In COVID-19 Death Rates – NPR
Podcast: Approach to shortness of breath
21 Oct, 2020 | 09:06h | UTC
Herd immunity and implications for SARS-CoV-2 control
20 Oct, 2020 | 01:44h | UTCHerd Immunity and Implications for SARS-CoV-2 Control – JAMA
Author Interview: Can We Count on Herd Immunity to Control COVID-19? – JAMA
Patient Page: What Is Herd Immunity? – JAMA
Commentary on Twitter
Herd immunity is real. It may be inevitable given our poor handling of COVID-19 and nature of the virus.
But to *deliberately* shoot for natural herd immunity (ie, without a vaccine) makes no sense.
Via @SaadOmer3 @InciYildirim11 @thehowie @JAMA_current https://t.co/PwWc1wMMzE pic.twitter.com/Ybn7vHFnt8
— Nicholas A. Christakis (@NAChristakis) October 19, 2020
Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?
20 Oct, 2020 | 01:38h | UTC
Commentary on Twitter
Side effect of #COVID19 surge: ignoring well established strategies
➡️ limit ABTs exposure vs resistances: MV/long #ICU stay
➡️ avoid toxicity: antivirals/antibiotics can have severe adverse effects/interactions
➡️ high mortality: improving outcome crucial https://t.co/FN3LtKKlsr pic.twitter.com/7KGbIOH3Uf— Intensive Care Medicine (@yourICM) October 17, 2020
Meta-analysis: The association of D-dimers with mortality, intensive care unit admission or ARDS in patients hospitalized with COVID-19
20 Oct, 2020 | 01:37h | UTC